1. Home
  2. STEP vs CRSP Comparison

STEP vs CRSP Comparison

Compare STEP & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo StepStone Group Inc.

STEP

StepStone Group Inc.

HOLD

Current Price

$42.86

Market Cap

5.0B

Sector

Finance

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$60.11

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEP
CRSP
Founded
2007
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.7B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
STEP
CRSP
Price
$42.86
$60.11
Analyst Decision
Buy
Buy
Analyst Count
7
17
Target Price
$80.71
$70.00
AVG Volume (30 Days)
1.5M
1.5M
Earning Date
05-07-2026
05-15-2026
Dividend Yield
3.23%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,174,830,000.00
$289,590,000.00
Revenue This Year
N/A
$1,603.19
Revenue Next Year
$32.34
$78.75
P/E Ratio
N/A
N/A
Revenue Growth
65.09
9169.85
52 Week Low
$40.27
$30.06
52 Week High
$77.80
$78.48

Technical Indicators

Market Signals
Indicator
STEP
CRSP
Relative Strength Index (RSI) 23.13 61.24
Support Level N/A $58.40
Resistance Level $64.38 $60.40
Average True Range (ATR) 3.32 3.03
MACD -1.32 1.16
Stochastic Oscillator 1.86 86.78

Price Performance

Historical Comparison
STEP
CRSP

About STEP StepStone Group Inc.

StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: